Kalaris Therapeutics Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $98.7M
- Price
- $4.15
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.73%
- Volume
- 81.2K
About
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Quick stats
Shares outstanding23.8M
Computed float5.6M
Float / shares23.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001754068
Websitehttps://kalaristx.com
AI Summary
AI-generated1/14
minorneutralearnings
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Kalaris reported Q2 2026 financial results, ending the period with $93.5 million in cash and cash equivalents to fund operations into Q4 2027.
The company is actively dosing patients in the Phase 1b/2 study of TH103 for neovascular AMD, with preliminary data expected in the first half of 2027.
R&D expenses increased to $9.0 million from $8.4 million year-over-year, driven by clinical activities, while net loss was $11.5 million.
Red flags
- Company is pre-revenue with ongoing net losses
- Cash burn of approximately $24.5 million over six months based on balance sheet change